利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.035 秒)

    COMBINATIONS COMPRISING EPOTHILONES AND PHARMACEUTICAL USES THEREOF
    15.
    发明申请
    COMBINATIONS COMPRISING EPOTHILONES AND PHARMACEUTICAL USES THEREOF 失效
    包含EPOTHILONES及其药物用途的组合

    公开(公告)号：US20090318390A1

    公开(公告)日：2009-12-24

    申请号：US12549947

    申请日：2009-08-28

    申请人： TianLing Chen ,  Diane Greeley ,  John David Rothermel ,  Markus Wartmann ,  Jeanette Marjorie Wood

    发明人： TianLing Chen ,  Diane Greeley ,  John David Rothermel ,  Markus Wartmann ,  Jeanette Marjorie Wood

    IPC分类号： A61K31/426 ,  A61K31/662 ,  A61K31/427 ,  A61K31/675 ,  A61P35/00

    CPC分类号： A61K31/663 ,  A61K31/427 ,  A61K31/502 ,  A61K31/555 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

    摘要： The invention relates to a combination which comprises (a) a bisphosphonate, a platinum compound or a vasculostatic compound and (b) an epothilone derivative of formula I wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl and Z is O or a bond, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition, a commercial package or product comprising such a combination; the use of such a combination for the preparation of a medicament for the delay of progression or treatment of a proliferative disease and to a method of treatment of a warm-blooded animal.

    摘要翻译： 本发明涉及一种组合，其包含（a）二膦酸盐，铂化合物或血管保护性化合物和（b）式I的埃坡霉素衍生物，其中A表示O或NRN，其中RN为氢或低级烷基，R为氢或 低级烷基和Z是O或键，其中活性成分（a）和（b）在每种情况下以游离形式或以药学上可接受的盐和任选的至少一种药学上可接受的载体的形式存在， 特别是延长进展或治疗增殖性疾病，特别是实体肿瘤疾病; 药物组合物，商业包装或包含这种组合的产品; 使用这种组合来制备用于延缓进展或治疗增殖性疾病的药物以及治疗温血动物的方法。

    COMBINATIONS COMPRISING EPOTHILONES AND PHARMACEUTICAL USES THEREOF
    16.
    发明申请
    COMBINATIONS COMPRISING EPOTHILONES AND PHARMACEUTICAL USES THEREOF 失效
    包含EPOTHILONES及其药物用途的组合

    公开(公告)号：US20080119529A1

    公开(公告)日：2008-05-22

    申请号：US12019294

    申请日：2008-01-24

    申请人： TianLing Chen ,  Diane Greeley ,  John Rothermel ,  Markus Wartmann ,  Jeanette Wood

    发明人： TianLing Chen ,  Diane Greeley ,  John Rothermel ,  Markus Wartmann ,  Jeanette Wood

    IPC分类号： A61K31/426 ,  A61P43/00 ,  C07D417/06

    CPC分类号： A61K31/663 ,  A61K31/427 ,  A61K31/502 ,  A61K31/555 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

    摘要： The invention relates to a combination which comprises (a) a bisphosphonate, a platinum compound or a vasculostatic compound and (b) an epothilone derivative of formula I wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition, a commercial package or product comprising such a combination; the use of such a combination for the preparation of a medicament for the delay of progression or treatment of a proliferative disease and to a method of treatment of a warm-blooded animal.

    摘要翻译： 本发明涉及一种组合，其包含（a）二膦酸盐，铂化合物或血管平滑化合物和（b）式I的埃坡霉素衍生物，其中A表示O或NR N，其中R

    Epothilone resistant cell lines
    17.
    发明申请
    Epothilone resistant cell lines 审中-公开
    埃博霉素抗性细胞系

    公开(公告)号：US20070134744A1

    公开(公告)日：2007-06-14

    申请号：US11650375

    申请日：2007-01-05

    申请人： Peter Atadja ,  Markus Wartmann ,  Yan Yan-Neale ,  Dalia Cohen

    发明人： Peter Atadja ,  Markus Wartmann ,  Yan Yan-Neale ,  Dalia Cohen

    IPC分类号： G01N33/574 ,  C12N5/08 ,  A61K31/427

    CPC分类号： G01N33/5011 ,  A61K47/6803 ,  A61K47/6851 ,  C12N5/0693 ,  C12N2503/02 ,  G01N33/5008 ,  G01N33/5014

    摘要： Epothilone resistant cells lines are disclosed. The invention also discloses methods for identifying substances which are cytotoxic to epothilone resistant cells or which are chemosensitizers or analogs of epothilone. The invention further discloses methods for identifying epothilone resistant cells and for inhibiting the growth of epothilone resistant cells in vitro and in vivo. The invention also discloses antibodies specific for epothilone resistant cells. Also disclosed is a method to identify microtubule stabilizing agents using the epothilone resistant cell lines disclosed.

    摘要翻译： 披露埃坡霉素抗性细胞系。 本发明还公开了鉴定对埃坡霉素抗性细胞具有细胞毒性或是埃坡霉素的化学敏化剂或类似物的物质的方法。 本发明还公开了用于鉴定埃坡霉素抗性细胞并用于在体外和体内抑制埃坡霉素抗性细胞生长的方法。 本发明还公开了对埃坡霉素抗性细胞特异的抗体。 还公开了使用公开的埃坡霉素抗性细胞系鉴定微管稳定剂的方法。

    Combination comprising N--4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent.
    19.
    发明申请
    Combination comprising N--4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent. 审中-公开
    包含N-4-（3-吡啶基）-2嘧啶胺和化学治疗剂的组合。

    公开(公告)号：US20120283206A1

    公开(公告)日：2012-11-08

    申请号：US13551079

    申请日：2012-07-17

    申请人： Christian Bruns ,  Elisabeth Buchdunger ,  Terence O'Reilly ,  Sandra Leta Siberman ,  Markus Wartmann ,  Gisbert Weckbecker

    发明人： Christian Bruns ,  Elisabeth Buchdunger ,  Terence O'Reilly ,  Sandra Leta Siberman ,  Markus Wartmann ,  Gisbert Weckbecker

    IPC分类号： A61K31/506 ,  A61K31/675 ,  A61P37/06 ,  A61K31/704 ,  A61P35/00

    CPC分类号： A61K45/06 ,  A61K31/506

    摘要： A method of treating a warm-blooded animal, especially a human, having a proliferative disease or acute or chronic transplant rejection comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) a chemotherapeutic agent selected from antineoplastic agents, especially as defined herein, and agents effective in treating acute or chronic transplant rejection; a combination comprising (a) and (b) as defined above and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease.

    摘要翻译： 一种治疗具有增殖性疾病或急性或慢性移植排斥反应的温血动物，特别是人的方法，包括向动物施用包含（a）N- {5- [4-（4-甲基 - 哌嗪子基） - 甲基） - 苯甲酰氨基] -2-甲基苯基} -4-（3-吡啶基）-2-嘧啶胺和（b）选自抗肿瘤剂，特别是本文所定义的化学治疗剂和有效治疗急性或慢性的药物 移植排斥反应 包含如上定义的（a）和（b）和任选的至少一种用于同时，分开或顺序使用的药学上可接受的载体的组合，特别是用于延缓进展或治疗增殖性疾病，特别是实体肿瘤疾病。